에 대한 최신 뉴스 So-Young Intl (NASDAQ:SY) 주식

So-Young Intl

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenues from information services fees and reservation services fees from medical aesthetic service providers.

News

Penny Stocks

Short Ideas

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

MDIA

SOHU

2024년 4월 8일 기준, 통신 서비스 섹터의 4개 주식이 모멘텀을 상당히 중요하게 생각하는 투자자들에게 실질적 경고를 보내고 있다고 볼 수 있다.RSI는 모멘텀 지표로, 이는 주가가 상승한 날의 주식 강도를 주가가 하락한 날의 주식 강도와 비교한다. 주식 가격의 변화와 비교할 때 주식이 단기간 내에 어떻게 움직일지에 대한 트레이더의 감을 더 잘 줄 수 있다. Benzinga Pro의 보고에 따르면 주로 RSI가 70 이상일 때 주식은 과매수로 간주된다.

2분기에 추락할 수 있는 최상위 기술 및 통신주 4종목

So-Young International Inc. - American Depository Shares

So-Young International Inc

SYRAH RESOURCES LTD by Syrah Resources Ltd.

Syrah Resources Ltd

Sydbank A/S

SAYONA MINING LTD ORD SHS by Sayona Mining Ltd.

Sayona Mining Ltd

Sybleu Inc

SYNTEC BIOFUEL INC by Syntec Biofuel, Inc.

SECURITY BANK CORP by Security Bank Corp.

Security Bank Corp

SYNERGY BRANDS INC by Synergy Brands, Inc.

Stock Yards Bancorp Inc

Synlogic Inc

SANYO CHEMICAL INDUS ORD by Sanyo Chemical Industries, Ltd.

Sanyo Chemical Industries Ltd

Delota Corp

SEYCHELLE ENVRNMNTL TECH by Seychelle Environmental Technologies, Inc.

Seychelle Environmental Technologies Inc

Synchrony Financial

AB Active ETFs, Inc. AB Short Duration High Yield ETF

Synchrony Financial 8.25% PRF PERPETUAL USD 25 - Dep rep 1/40 Ser B

Synchrony Financial Depositary Shares, each Representing a 1/40th Interest in a Share of 5.625% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A

Synchrony Financial Depositary Shares Each Representing a 1/40th Interest in a Share of 8.250% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B

Sylla Gold Corp

Synairgen PLC

Sygnity SA

SKYHARBOUR RES LTD ORD by Skyharbour Resources Ltd.

Skyharbour Resources Ltd

SYMPHONY HOLDINGS ORD by Symphony Holdings, Ltd.

Symphony Holdings Ltd

Synthomer PLC ADR

Synthomer PLC

SYNERGIE WELLNESS PRODS by Synergie Wellness Products, Inc.

Synergie Wellness Products Inc

Symrise AG

Syntax ETF Trust Stratified Total Market II ETF

SYNBIO INTERNATIONAL INC by Synbio International Inc.

Synbio International Inc

Stryker Corp

SOLITON SYSTEMS KK ORD by Soliton Systems

Soliton Systems KK

SKY NETWORK TV by Sky Network Television Ltd.

Sky Network Television Ltd

Cambria Shareholder Yield ETF

Sylo - United States Dollar

Symbotic Inc

SYMBIO PHARMS LTD S/ADR by Symbio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

Synapse - United States Dollar

Synaptics Inc

Putnam ETF Trust Putnam BioRevolution ETF

SYNC Network

SYNTHESIS ENERGY SYS INC by Synthesis Energy Systems, Inc.

Synthesis Energy Systems Inc

Synchro Food Co Ltd

SYNEOS HEALTH INC CL A

SYNVISTA THERAPEUTICS INC by Synvista Therapeutics, Inc.

DAY TRADEXCHANGE INC by Day TradeXchange, Inc.

Day TradeXchange Inc

SYMPHONY INTL HLDGS ORD by Symphony International Holdings Ltd.

Symphony International Holdings Ltd

SYENSQO SA U/ADR by Syensqo SA

Silynxcom Ltd

SANYO INDUSTRIES LTD by SANYO INDUSTRIES LTD

Sanyo Industries Ltd

SANYO SPECIAL STEEL ORD by Sanyo Special Steel Co., Ltd.

Sanyo Special Steel Co Ltd

Systena Corp

Sypris Solutions Inc

Scrypt Inc

LIAONING SHUIYUN QINGHE by Liaoning Shuiyun Qinghe Rice Industry Co., Ltd.

Liaoning Shuiyun Qinghe Rice Industry Co Ltd

Syra Health Corp

Spyre Therapeutics Inc

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals Inc

Sacyr SA

Syscoin

Sysorex Inc

SYLA Technologies Co., Ltd. - American Depositary Shares

SYLA Technologies Co Ltd

Siyata Mobile Inc

ANBC Inc

Syntax ETF Trust Stratified US Total Mkt ETF

SYNOVICS PHARMS INC by Synovics Pharmaceuticals, Inc.

Synovics Pharmaceuticals Inc

SYCAMORE VENTURES INC by Sycamore Ventures, Inc.

Sycamore Ventures Inc

SYNNEX TECH INTL ORD by Synnex Technology International Corp.

SYNNEX TECH INTL GDR 144A by Synnex Technology International Corp.

Synnex Technology International Corp

Synodon Inc

SYNNEX TECH INTL GDR by Synnex Technology International Corp.

Sysco Corp

SYN PROP E TECH SA S/GDR by SYN Prop e Tech SA

SYN Prop E Tech SA

Sylogist Ltd

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

So-Young International Inc. (SY) Q1 2024 Earnings Call Transcript

Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more

So-Young International reports Q2 results

Today, several major companies are expected to report earnings: Buckle (BKE) and So-Young International (SY). Ahead of earnings, TipRanks shows you...

Options Volatility and Implied Earnings Moves Today, August 23, 2024

So-Young International (SY) has released an update. So-Young International Inc. reported a slight revenue decline to RMB407.4 million in Q2 2024 fr...

So-Young's Strategic Shift Leads to Profitable Q2

So-Young International Inc. (SY) Q2 2024 Earnings Call Transcript

So-Young International (SY) has released an update. So-Young International Inc., a prominent player in China's medical aesthetics social community,...

Comments

So-Young Intl

뉴스

에 대한 최신 뉴스 So-Young Intl (NASDAQ:SY) 주식

화요일, 4월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌